• Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor investor investor

€0.0

round
investor

€0.0

round
investor investor investor

€0.0

round
investor investor investor investor investor investor investor

€0.0

round
investor

€0.0

Valuation: €0.0

7.9x EV/Revenue

round
investor investor investor investor investor investor investor investor investor investor

€0.0

round

€2.5m

Grant
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2020202120222023
Revenues0000000000000000
% growth-55 %29 %23 %
EBITDA0000000000000000
% EBITDA margin(38 %)---
Profit0000000000000000
% profit margin(42 %)---
EV0000000000000000
EV / revenue00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x
R&D budget0000000000000000

Source: Company filings or news article, Dealroom estimates

Notes (0)
More about Croivalve
Made with AI
Edit

Croivalve is a pioneering medical technology startup focused on addressing severe Tricuspid Regurgitation (TR), a condition affecting the heart's tricuspid valve. This condition predominantly impacts elderly patients, leading to symptoms like fatigue, limited exercise tolerance, peripheral edema (swelling), and abdominal swelling. These symptoms often result in frequent hospitalizations and a significantly increased risk of mortality.

The company operates in the healthcare and medical devices market, specifically targeting cardiovascular diseases. Croivalve's primary product is the DUO Tricuspid Coaptation Valve system, a minimally invasive solution designed to treat severe TR. This innovative system combines repair and replacement techniques to provide a comprehensive treatment option. The DUO System consists of two main components: an Anchor System and a Coaptation Valve. The Anchor System connects to the Coaptation Valve and includes a support catheter that can be adjusted and locked into position. This system is anchored within the Superior Vena Cava (SVC) using a stent, allowing for respiratory and cardiac motion. The support catheter has a distal implanted section and a proximal delivery section, which is removed at the end of the procedure.

Croivalve's business model revolves around developing and commercializing this advanced medical device. The company generates revenue by selling the DUO Tricuspid Coaptation Valve system to hospitals and healthcare providers. Given the significant unmet clinical need and the lack of effective surgical treatments for TR, Croivalve's solution offers a promising alternative to traditional medical therapy, which only provides temporary relief.

In summary, Croivalve is addressing a critical gap in cardiovascular healthcare with its innovative, minimally invasive treatment for severe Tricuspid Regurgitation. The company's focus on improving patient outcomes and quality of life positions it as a key player in the medical devices market.

Keywords: Tricuspid Regurgitation, minimally invasive, elderly patients, cardiovascular, medical devices, DUO System, Anchor System, Coaptation Valve, healthcare, innovation.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo